These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 29520442)

  • 1. CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer.
    Lee SJ; Jun SY; Lee IH; Kang BW; Park SY; Kim HJ; Park JS; Choi GS; Yoon G; Kim JG
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1005-1014. PubMed ID: 29520442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed death ligand 1/indoleamine 2,3-dioxygenase 1 expression and tumor-infiltrating lymphocyte status in renal cell carcinoma with sarcomatoid changes and rhabdoid features.
    Kiyozawa D; Takamatsu D; Kohashi K; Kinoshita F; Ishihara S; Toda Y; Eto M; Oda Y
    Hum Pathol; 2020 Jul; 101():31-39. PubMed ID: 32360490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic implication of CD274 (PD-L1) protein expression in tumor-infiltrating immune cells for microsatellite unstable and stable colorectal cancer.
    Lee KS; Kwak Y; Ahn S; Shin E; Oh HK; Kim DW; Kang SB; Choe G; Kim WH; Lee HS
    Cancer Immunol Immunother; 2017 Jul; 66(7):927-939. PubMed ID: 28405764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions.
    Toda Y; Kohashi K; Yamada Y; Yoshimoto M; Ishihara S; Ito Y; Iwasaki T; Yamamoto H; Matsumoto Y; Nakashima Y; Mawatari M; Oda Y
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2607-2620. PubMed ID: 32388585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype.
    Takada K; Toyokawa G; Kinoshita F; Jogo T; Kohashi K; Wakasu S; Ono Y; Tanaka K; Oba T; Osoegawa A; Tagawa T; Azuma K; Okamoto I; Shimokawa M; Oda Y; Mori M
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2639-2650. PubMed ID: 32405745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas.
    Zhang ML; Kem M; Mooradian MJ; Eliane JP; Huynh TG; Iafrate AJ; Gainor JF; Mino-Kenudson M
    Mod Pathol; 2019 Apr; 32(4):511-523. PubMed ID: 30367104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune infiltration in renal cell carcinoma.
    Zhang S; Zhang E; Long J; Hu Z; Peng J; Liu L; Tang F; Li L; Ouyang Y; Zeng Z
    Cancer Sci; 2019 May; 110(5):1564-1572. PubMed ID: 30861269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors.
    Marisa L; Svrcek M; Collura A; Becht E; Cervera P; Wanherdrick K; Buhard O; Goloudina A; Jonchère V; Selves J; Milano G; Guenot D; Cohen R; Colas C; Laurent-Puig P; Olschwang S; Lefèvre JH; Parc Y; Boige V; Lepage C; André T; Fléjou JF; Dérangère V; Ghiringhelli F; de Reynies A; Duval A
    J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy.
    Takada K; Kohashi K; Shimokawa M; Haro A; Osoegawa A; Tagawa T; Seto T; Oda Y; Maehara Y
    Lung Cancer; 2019 Feb; 128():26-32. PubMed ID: 30642449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined prognostic value of CD274 (PD-L1)/PDCDI (PD-1) expression and immune cell infiltration in colorectal cancer as per mismatch repair status.
    Ahtiainen M; Wirta EV; Kuopio T; Seppälä T; Rantala J; Mecklin JP; Böhm J
    Mod Pathol; 2019 Jun; 32(6):866-883. PubMed ID: 30723299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytolytic Activity Score to Assess Anticancer Immunity in Colorectal Cancer.
    Narayanan S; Kawaguchi T; Yan L; Peng X; Qi Q; Takabe K
    Ann Surg Oncol; 2018 Aug; 25(8):2323-2331. PubMed ID: 29770915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
    Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
    J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1.
    Ho HL; Chou TY; Yang SH; Jiang JK; Chen WS; Chao Y; Teng HW
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1785-1794. PubMed ID: 31129768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry.
    Park Y; Seo AN; Koh J; Nam SK; Kwak Y; Ahn SH; Park DJ; Kim HH; Lee HS
    Oncoimmunology; 2021; 10(1):1954761. PubMed ID: 34367732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
    Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
    Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Role of Tumoral PD-L1 and IDO1 Expression, and Intratumoral CD8+ and FoxP3+ Lymphocyte Infiltrates in 132 Primary Cutaneous Merkel Cell Carcinomas.
    Donizy P; Wu CL; Kopczynski J; Pieniazek M; Biecek P; Ryś J; Hoang MP
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma.
    Rosenbaum MW; Gigliotti BJ; Pai SI; Parangi S; Wachtel H; Mino-Kenudson M; Gunda V; Faquin WC
    Endocr Pathol; 2018 Mar; 29(1):59-67. PubMed ID: 29372535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of tumour-infiltrating CD8+ lymphocytes in rectal cancer after neoadjuvant chemoradiation: is indoleamine-2,3-dioxygenase (IDO1) a friend or foe?
    Schollbach J; Kircher S; Wiegering A; Seyfried F; Klein I; Rosenwald A; Germer CT; Löb S
    Cancer Immunol Immunother; 2019 Apr; 68(4):563-575. PubMed ID: 30671614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape.
    Blanc-Durand F; Genestie C; Galende EY; Gouy S; Morice P; Pautier P; Maulard A; Mesnage S; Le Formal A; Brizais C; Richardson M; Leary A
    Gynecol Oncol; 2021 Jan; 160(1):279-284. PubMed ID: 33162175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.